Akamis Bio (IP Group plc) Receives FDA Fast Track Designation for NG-350A in Locally Advanced Rectal Cancer

Reuters10-14

Akamis Bio (IP Group plc) Receives FDA <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation for NG-350A in Locally Advanced Rectal Cancer

Akamis Bio, a portfolio company of IP Group plc, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy NG-350A. This designation is for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), which represents about 90% of LARC cases. NG-350A is an intravenously delivered oncolytic immunotherapy developed to stimulate a targeted immune response in tumors by inducing expression of a CD40 agonist monoclonal antibody. The therapy is currently being assessed in combination with chemoradiotherapy in the ongoing Phase 1b FORTRESS study. The FDA's Fast Track designation is intended to expedite the development and review process for promising treatments addressing serious unmet medical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575121631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575121631","market":"us","top_or_hot":-1,"title":"Akamis Bio (IP Group plc) Receives FDA Fast Track Designation for NG-350A in Locally Advanced Rectal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akamis Bio (IP Group plc) Receives FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation for NG-350A in Locally Advanced Rectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akamis Bio, a portfolio company of IP Group plc, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy NG-350A. This designation is for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), which represents about 90% of LARC cases. NG-350A is an intravenously delivered oncolytic immunotherapy developed to stimulate a targeted immune response in tumors by inducing expression of a CD40 agonist monoclonal antibody. The therapy is currently being assessed in combination with chemoradiotherapy in the ongoing Phase 1b FORTRESS study. The FDA's Fast Track designation is intended to expedite the development and review process for promising treatments addressing serious unmet medical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akamis Bio (IP Group plc) Receives FDA Fast Track Designation for NG-350A in Locally Advanced Rectal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkamis Bio (IP Group plc) Receives FDA Fast Track Designation for NG-350A in Locally Advanced Rectal Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Akamis Bio (IP Group plc) Receives FDA <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation for NG-350A in Locally Advanced Rectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Akamis Bio, a portfolio company of IP Group plc, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy NG-350A. This designation is for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), which represents about 90% of LARC cases. NG-350A is an intravenously delivered oncolytic immunotherapy developed to stimulate a targeted immune response in tumors by inducing expression of a CD40 agonist monoclonal antibody. The therapy is currently being assessed in combination with chemoradiotherapy in the ongoing Phase 1b FORTRESS study. The FDA's Fast Track designation is intended to expedite the development and review process for promising treatments addressing serious unmet medical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO.UK","symbol_name":"IP GROUP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL50VnG4:1","article_id":"2575121631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575121631","pubTimestamp":1760448805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Akamis Bio, a portfolio company of IP Group plc, has received Fast Track designation from the U.S. Food and Drug Administration  for its investigational therapy NG-350A. This designation is for the treatment of mismatch repair-proficient  locally advanced rectal cancer , which represents about 90% of LARC cases. NG-350A is an intravenously delivered oncolytic immunotherapy developed to stimulate a targeted immune response in tumors by inducing expression of a CD40 agonist monoclonal antibody. The therapy is currently being assessed in combination with chemoradiotherapy in the ongoing Phase 1b FORTRESS study. The FDA's Fast Track designation is intended to expedite the development and review process for promising treatments addressing serious unmet medical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes onl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO.UK":"IP GROUP","BK5078":"资产管理与托管银行"},"translate_title":"Akamis Bio(IP Group plc)获得FDA快速通道指定NG-350A治疗局部晚期直肠癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO.UK":0.9},"content_text":"Akamis Bio (IP Group plc) Receives FDA Fast Track Designation for NG-350A in Locally Advanced Rectal Cancer\n    \n\n        Akamis Bio, a portfolio company of IP Group plc, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy NG-350A. This designation is for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), which represents about 90% of LARC cases. NG-350A is an intravenously delivered oncolytic immunotherapy developed to stimulate a targeted immune response in tumors by inducing expression of a CD40 agonist monoclonal antibody. The therapy is currently being assessed in combination with chemoradiotherapy in the ongoing Phase 1b FORTRESS study. The FDA's Fast Track designation is intended to expedite the development and review process for promising treatments addressing serious unmet medical needs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575121631","isCrawlerRequest":true}